Peimisine ameliorates DSS-induced colitis by suppressing Jak-Stat activation and alleviating gut microbiota dysbiosis in mice
- J Pharm Pharmacol. 2023 Nov 25:rgad091. doi: 10.1093/jpp/rgad091.
- 1. Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, Jilin 130117, P. R. China.
- 2. Medical College, Yanbian University, Yanji 133002, P. R. China.
- 3. Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, Jilin 130122, P. R. China.
Objectives: Inflammatory cytokine secretion and gut microbiota dysbiosis play crucial roles in ulcerative colitis. In this research, the protective effects of peimisine on colitis mice were investigated.
Methods: The protective effects were evaluated by the disease activity index, colonic length, hematoxylin-eosin, and AB/PAS Staining. The protective mechanisms were analyzed by ELISA, Western-blot, immunohistochemistry staining, immunofluorescence staining, and 16S rRNA gene analysis.
Key findings: The results showed that peimisine treatment could reduce the disease activity index, prevent colonic shortening, and alleviate colon tissue damage. Peimisine treatment also decreased the levels of MCP-1, IL-1β, IL-6, IFN-γ, TNF-α and affected macrophage polarization and Th17/Treg cell balance by downregulating the expression of JAK1/2, p-jak1/2, STAT1/3, and p-stat1/3. Moreover, peimisine treatment significantly increased the abundances of beneficial microbes (e.g. Ruminococcaceae UCG-014 and Lachnospiraceae_NK4A136_group) and decreased the abundances of harmful microbes (e.g. Bacteroides and Escherichia).
Conclusions: Peimisine can ameliorate colitis by inhibiting Jak-Stat signaling pathway, reversing gut microbiota alterations, suppressing macrophage M1 polarization, maintaining the Th17/Treg cell balance, and reducing sustained inflammatory cytokines-related inflammatory injury.
-
Cat. No.Product NameDescriptionTargetResearch Area
-